制御不能高血圧に対する新型トリプル・シングル・ピルの有効性と安全性: OPTION TREAT試験
Vagner Madrini1, Caio A M Tavares2, Monica T A Albuquerque1
1Hospital Israelita Albert Einstein, São Paulo, Brazil.
JACC. Advances
|September 2, 2025
まとめ
カンデサルタン・シレキセチル,アムロディピン,およびクロルタリドンの新しい単一錠剤の組み合わせは,制御不能の高血圧患者の血圧を効果的に低下させました. このトリプルセラピーは,既存の治療法と比較して優れた安全性プロファイルを示した.
科学分野:
- 心血管医学
- 薬理学について
- 臨床試験
背景:
- 高血圧の管理には 新しい治療法が必要です
- 単一錠剤の組み合わせは,治療の順守と有効性を高めます.
- 既存の二重治療は,特定の患者集団では不十分かもしれません.
研究 の 目的:
- 新型トリプル単錠治療の有効性と安全性を評価する.
- カンデサルタン・シレキセチル,アムロディピン,クロルタリドンの組み合わせを有効な対照薬と比較する.
- 制御不能の高血圧患者の治療結果を評価する.
主な方法:
- ランダム化,ダブルブラインド,ダブルダミー,非劣等性試験 (OPTION TREAT) が実施されました.
- 703人の無制御高血圧患者は,実験用トリプルピルまたは12週間の有効な対照薬をランダムに投与されました.
- 主な評価は,診療室での静脈動脈血圧の基準値から12週間の変化でした.
主要な成果:
- 新薬のトリプルピルは,活薬 (対照薬) と比較してシストリック血圧 (-22. 6mmHg) をより大きく低下させた.
- 2つのグループで,ダイアストリック血圧の有意な低下が観察され,実験グループでは効果がより顕著でした.
- 新型トリプルセラピーでは高いアデンスと低頻度の重篤な有害事象が報告されました.
結論:
- 新規の三重単錠併用療法により,制御不能高血圧の患者で血圧のコントロールが著しく改善されました.
- この新薬は12週間の治療で好ましい安全性を示した.
- この発見は高血圧の有効な治療法としてこの新しいトリプルセラピーの使用を支持する.
関連する概念動画
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Hypertension IV: Drug Therapy and Lifestyle Modifications
37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Hypertension III: Clinical Manifestations and Diagnostic Studies
48
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
48
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
247
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
247


